Basit öğe kaydını göster

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

dc.contributor.authorGleixner, Karoline
dc.contributor.authorNekvindova, Lucie
dc.contributor.authorElberink, Hanneke O.
dc.contributor.authorGorska, Aleksandra
dc.contributor.authorLange, Magdalena
dc.contributor.authorHartmann, Karin
dc.contributor.authorIllerhaus, Anja
dc.contributor.authorBonifacio, Massimiliano
dc.contributor.authorPerkins, Cecelia
dc.contributor.authorElena, Chiara
dc.contributor.authorNiedoszytko, Marek
dc.contributor.authorvan Anrooij, Bjorn
dc.contributor.authorReiter, Andreas
dc.contributor.authorGotlib, Jason
dc.contributor.authorKluin-Nelemans, Hanneke C.
dc.contributor.authorMayer, Jiri
dc.contributor.authorDoubek, Michael
dc.contributor.authorValent, Peter
dc.contributor.authorMalcovati, Luca
dc.contributor.authorFortina, Anna B.
dc.contributor.authorYavuz, Akif
dc.contributor.authorHagglund, Hans
dc.contributor.authorMattsson, Mattias
dc.contributor.authorPanse, Jens
dc.contributor.authorJaekel, Nadja
dc.contributor.authorKilbertus, Alex
dc.contributor.authorHermine, Olivier
dc.contributor.authorArock, Michel
dc.contributor.authorFuchs, David
dc.contributor.authorSabato, Vito
dc.contributor.authorBrockow, Knut
dc.contributor.authorBretterklieber, Agnes
dc.contributor.authorShoumariyeh, Khalid
dc.contributor.authorJawhar, Mohamad
dc.contributor.authorZanotti, Roberta
dc.contributor.authorBonadonna, Patrizia
dc.contributor.authorCaroppo, Francesca
dc.contributor.authorZink, Alexander
dc.contributor.authorTriggiani, Massimo
dc.contributor.authorParente, Roberta
dc.contributor.authorvon Bubnoff, Nikolas
dc.contributor.authorTrizuljak, Jakub
dc.contributor.authorSperr, Wolfgang R.
dc.date.accessioned2021-03-02T17:27:39Z
dc.date.available2021-03-02T17:27:39Z
dc.date.issued2020
dc.identifier.citationTrizuljak J., Sperr W. R. , Nekvindova L., Elberink H. O. , Gleixner K., Gorska A., Lange M., Hartmann K., Illerhaus A., Bonifacio M., et al., "Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification", ALLERGY, cilt.75, sa.8, ss.1927-1938, 2020
dc.identifier.issn0105-4538
dc.identifier.otherav_834a1297-e019-4422-9ec9-0671acbd240f
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3808
dc.identifier.urihttps://doi.org/10.1111/all.14248
dc.description.abstractBackground: In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited patient numbers, have also shown that the clinical course in ISM is stable and comparable to that of cutaneous mastocytosis (CM). The aim of this project was to compare the prognosis of patients with ISM with that of patients with CM.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectKlinik Tıp (MED)
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectALERJİ
dc.titleClinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification
dc.typeMakale
dc.relation.journalALLERGY
dc.contributor.departmentUniversity of Freiburg , ,
dc.identifier.volume75
dc.identifier.issue8
dc.identifier.startpage1927
dc.identifier.endpage1938
dc.contributor.firstauthorID2286006


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster